Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical ... ( SAN FRANCISCO March 5 -- On the surf...)

Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical Conditions

Date:3/5/2009

SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- On the surface, the thick, red, scaly, itchy plaques of psoriasis -- which have been shown to have a significant negative impact on a person's overall quality of life -- may not appear to pose a serious health risk for patients. However, a growing body of research suggests that psoriasis patients are at an increased risk of developing serious medical conditions, including cardiovascular disease and diabetes, particularly when their psoriasis is severe.

Speaking today at the 67th Annual Meeting of the American Academy of Dermatology (Academy), dermatologist Joel M. Gelfand, MD, MSCE, FAAD, assistant professor of dermatology at the University of Pennsylvania School of Medicine in Philadelphia, spoke about this complex skin condition and its relationship to other serious medical conditions.

Dr. Gelfand explained that for the last two decades, research has shown that excessive inflammation is a critical feature of psoriasis. This discovery has led to innovative approaches to treating psoriasis, with therapies targeting selected areas of the immune system that are over-active in psoriasis patients. Excess inflammation also is present in other common conditions, such as hardening of the arteries, heart attacks, stroke, obesity and diabetes -- which may explain why some psoriasis patients may be at an increased risk for developing these other serious conditions.

Studies show the link between patients with severe psoriasis and diabetes, heart attack and coronary artery disease occurs independent of traditional risk factors for these other conditions -- such as obesity, smoking or high blood pressure.

Furthermore, Dr. Gelfand's recent research suggests that patients with severe psoriasis may have shorter life expectancies than non-psoriasis patients. Specifically, he found that those with severe psoriasis may die three to five years earlie
'/>"/>

SOURCE American Academy of Dermatology
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties
2. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
3. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
4. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
5. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
6. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
7. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
8. OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
11. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis

Post Your Comments:

(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...

(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012 Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...

(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...

Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2 Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4

[0] Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting [0] Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream [0] Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.

... blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 ... reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the ... which leads to an increase in blood flow and oxygen supply,to ...

... Joint Venture Between Bristol-Myers Squibb, Company ... in HIV Treatment -, PRINCETON, N.J. and ... Company (NYSE: BMY ) and Gilead Sciences, ... Canada has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir ...

New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...

(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...

(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...

(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...

(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...

Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2 Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2 Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4 Health News:Cleft lip/palate cause much more than cosmetic problems 2

[0] Landmark textbook on health care and the US legal system released [0] Aggregating instead of stabilizing: New insights into the mechanisms of heart disease [0] Viral infections in infancy are not associated with wheezing symptoms in later childhood [0] Mayo Clinic urologists present findings at American Urological Association Annual Meeting [0] Cleft lip/palate cause much more than cosmetic problems

... Inc. (NYSE: CSV ) today announced results for the first quarter ended March 31, 2009. Highlights from continuing operations for ... in millions, except per share amounts) , , ... Q1, ... Change, ...

... Inc.,s parent company, Team Finance LLC (the "Company"), today announced ... less provision for uncollectibles ("revenue less provision") in the first ... million in the first quarter of 2008. Same contract ... million from $305.5 million in the same period a year ...

... of these meds with their doctor, cardiac group says ... takes the clot-preventing drug Plavix after receiving a stent ... medications called proton pump inhibitors (PPIs), if possible, a ... blockbuster acid reflux medications such as Nexium, Prevacid and ...

... Contributions emphasize need for improved mental health services ... The Regence Foundation announced today it awarded $390,000 ... Idaho, Oregon, Utah and Washington. Five of the ... organizations nominated by Regence employees as part of ...

... age of those hospitalized in U.S. is 15, CDC says ... majority of U.S. cases continue to be mild, those who ... atypically young, health officials said Wednesday. , In fact, the ... which is younger than occurs in regular seasonal flu, U.S. ...

... The following was released today by Americans for ... National Institute for Occupational Safety and Health (NIOSH) ... dangerous levels of secondhand smoke at work. NIOSH recommends ... casinos is safe for workers to breathe. In 2005, ...

Carriage Services Announces First Quarter 2009 Results Team Finance LLC Announces First Quarter 2009 Results Plavix, Heartburn Drugs May Be Risky Combination Regence Foundation Grants $390,000 to Improve Health Care Safety Net Younger Age of Severe Swine Flu Cases Worries Experts No Safe Bets for Casino Workers: NIOSH Study Shows Casino Workers Face Toxic Conditions

Slick® Disposable Endotracheal Stylet, Nylon-coated wire, Malleable core, Sureloc Stop helps maintain desired length for patient safety. Handle forming capability for better grip. Sterile. Single...

Stylet - Infant Stainless Steel, Flexible, Non-Sterile, Latex Free, With stop, Suitable for tubes 2.0 mm I.D. or larger....

... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...

All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....

Medicine Products:

Slick® Disposable Endotracheal Stylet 6 Fr Endotracheal Tube Stylet - Infant Lighted Pediatric Stylet - Sterile Blue Line® Intubation Stylet 5.0 mm 7.0 mm

Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical ...( SAN FRANCISCO March 5 -- On the surf...),Health